Matthew Galsky, MD, on infrastructure and education in BCG/ICI integration

In the following video, Matthew D. Galsky, MD, emphasizes that the successful integration of BCG/immune checkpoint inhibitor (ICI) combinations in BCG-naive non–muscle invasive bladder cancer (NMIBC) will depend on logistics, infrastructure, team education, and a coordinated recognition of immune-related adverse events across urology and oncology practices. Galsky is a professor of medicine at the Icahn School of Medicine at Mount Sinai and the director of GU medical oncology at the Tisch Cancer Center in New York, New York.